123
4 Page 4 of 17
56...17
Migraine is a prevalent neurological disease, affecting 38 million adults in the U.S., or 13% of the population. This illness exacts a substantial toll on patients, compromising their ability to perform activities of daily living. More than 90% of
Member: $0.00
Non-Member: $0.00
1.50 AAPA Category 1 CME credit
Juvenile idiopathic arthritis (JIA) is an arthritis of unknown origin that affects approximately 300,000 children and teens in the United States. JIA has a serious impact on quality of life and can continue into adulthood in some patients. The diagnosis of JIA is challenging, as it is a diagnosis of exclusion and can easily be missed, often leading to a delay in treatment. The management of JIA involves a multidisciplinary team that typically includes a rheumatologist; however, an ongoing and increasing shortage of rheumatology professionals necessitates the involvement of advanced practice providers—including nurse practitioners and physician assistants—in the management and transitioning of care from pediatric to adult care settings. The current state of care is evolving with new therapies and emerging guidelines, and clinicians who manage patients with JIA must remain up to date on available therapies and treatment recommendations. In this interactive activity, expert faculty discuss the etiology and classification of Juvenile Idiopathic Arthritis (JIA) as well as cases that will help clinicians diagnose, classify, and optimally threat their patients with JIA.
Member: $0.00
Non-Member: $0.00
1.00 AAPA Category 1 CME credit
Migraine is a prevalent neurological disease, affecting 38 million adults in the U.S., or 13% of the population. This illness exacts a substantial toll on patients, compromising their ability to perform activities of daily living. More than 90% of
Member: $0.00
Non-Member: $0.00
0.75 AAPA Category 1 CME credit
Migraine is a prevalent neurological disease, affecting 38 million adults in the U.S., or 13% of the population. This illness exacts a substantial toll on patients, compromising their ability to perform activities of daily living. More than 90% of
Member: $0.00
Non-Member: $0.00
0.75 AAPA Category 1 Self-Assessment CME credit
Barriers to Cervical Cancer Screening Among Immigrants | Treating Patients With Moderate-To-Severe Psoriasis Vulgaris
Member: $0.00
Non-Member: $25.00
1.00 AAPA Category 1 CME credit
This monograph is a supplement to the JAAPA March 2022 issue. Psoriasis and psoriatic arthritis (PsA) are chronic inflammatory diseases that can substantially undermine the functional abilities and quality of life of affected individuals. Psoriasis
Member: $0.00
Non-Member: $0.00
1.50 AAPA Category 1 CME credit
Primary Care Migraine© is a free web and app-based training program that provides primary care professionals with continuing medical education (CME) credits while learning about the most cutting-edge treatments and preventative protocols for migraine
Member: $0.00
Non-Member: $0.00
2.00 AMA PRA Category 1
Therapeutic inertia is the failure to advance or deintensify the treatment regimen when a patient’s therapeutic goals are not met. Earlier achievement of glycemic control is critical for improving outcomes for patients with diabetes. There are simple things you can do right now to more rapidly optimize treatment and to remove barriers to care plan adherence – both essential to busting therapeutic inertia. The ADA's Overcoming Therapeutic Inertia (OTI) CE Certificate program is designed to empower clinicians caring for people with diabetes with knowledge and strategies to be a barrier buster.
Member: $125.00
Non-Member: $125.00
11.75 AAPA Category 1 CME credit
During this module, Dr. Kevin Pantalone, Director of Diabetes Initiatives at Cleveland Clinic, and Dr. Chhavi Mehta, Associate Medical Director of Quality at Sutter Diabetes Clinical Improvement Community, will provide practical strategies and tips to help you identify and engage patients in your practice who may be experiencing, or be at risk of experiencing therapeutic inertia. The presenters will discuss options for using various electronic health record platforms as well as low tech approaches. Discussion about leveraging technology to improve the quality and frequency of patient engagement will also be included.
Member: $15.00
Non-Member: $15.00
1.00 AAPA Category 1 CME credit
During this module our presenters will discuss evidence supporting the value of timely therapy optimization to achieving glycemic targets and the legacy effect in type 2 diabetes. This discussion will focus on integrating the ADA type 2 diabetes medication algorithm with effective intensification and deintensification guidance for reducing therapeutic inertia. In order to encourage collaborative decision making between patients, team members, and primary care providers, presenters will provide practical techniques for how and when to use new tools and technology. These include CGM, time in range, and updated medication delivery systems.
Member: $15.00
Non-Member: $15.00
1.00 AAPA Category 1 CME credit
123
4 Page 4 of 17
56...17